Clinical Trials Logo

Filter by:
NCT ID: NCT05367232 Recruiting - Clinical trials for Patients With Advanced Solid Tumors

A Study of ICP-033 in Patients With Advanced Solid Tumors

Start date: February 25, 2022
Phase: Phase 1
Study type: Interventional

A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-033 Tablets in Patients with Advanced Solid Tumors.

NCT ID: NCT05367206 Recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial

N6C
Start date: March 14, 2022
Phase: Phase 3
Study type: Interventional

Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma >4 cm in greatest dimension and/or lymph node >2cm in short axis.

NCT ID: NCT05367063 Recruiting - Clinical trials for Cardiovascular Diseases

Canagliflozin and Myocardial Micro-perfusion

Start date: January 5, 2022
Phase: Phase 4
Study type: Interventional

Recently, large clinical intervention studies have demonstrated the cardiovascular protective effects on of sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin, dapagliflozin, and canagliflozin in reduction of cardiovascular and all-cause mortality, coincident with a significant reduction in heart failure hospitalizations. Therefore, SGLT2i had been recommended as a therapeutic drug for diabetic patients to reduce the occurrence of cardiovascular events. However, the mechanism of these benefits remains unclear at the present time. Myocardial fibrosis is not only an important physiopathological mechanism of heart failure, but also has been shown to be closely associated with the risk of heart failure-related hospitalization and death, especially in patients with T2D. However, whether SGLT2i can exert cardioprotective effects by improving myocardial fibrosis remains to be further investigated. In recent years, the development of cardiac magnetic resonance (CMR) technology enables to detect focal and diffuse fibrosis in myocardial tissue, which makes it possible to systematically explore the role of SGLT2i on myocardial fibrosis. Although several studies including EMPA-HEART, SUGAR-DM-HF have explored the effects of SGLT2i on cardiac structure and function, these studies didn't reach consistent results. In addition, more scarce studies have investigated the effects of SGLT2i on both focal and diffuse fibrosis. At present, whether SGLT2i treatment can change the relevant indicators of myocardial fibrosis in people with diabetes and cardiovascular risk factors has not yet been reported. In addition, previous studies mainly focus on empagliflozin and dapagliflozin, and studies on canagliflozin are still very scarce. Therefore, this study intends to explore the effects of canagliflozin on myocardial fibrosis and other structures and functions of the heart in patients with type 2 diabetes mellitus and high cardiovascular risk factors.

NCT ID: NCT05366478 Recruiting - Melanoma Clinical Trials

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

NCT ID: NCT05366335 Recruiting - Clinical trials for Irritable Bowel Syndrome

Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease

CPIFGD
Start date: July 4, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this project is to study the the efficacy and safety of probiotics implantation through infusion during colonoscopy in the treatment of functional constipation and irritable bowel syndrome. The study is a single-center, prospective, randomized, single-blind, controlled, cohort study. The invesitigators plan to enroll 80 patients with functional constipation and 80 patients with irritable bowel syndrome. The invesitigators will randomize the included study subjects. The experimental group receive basic treatment and a single infusion of probiotics through colonoscopy. The control group receive basic treatment and a single injection of normal saline through colonoscopy. The invesitigators will follow up the patients for 8-12 weeks. The primary endpoint is the efficacy of the single colonoscopic probiotics infusion in functional constipation and irritable bowel syndrome patients. The secondary endpoint is the safety of the single colonoscopic probiotics infusion in functional constipation and irritable bowel syndrome patients. Other exploratory objectives include the alterations in clinical indicators, fecal microbiota, and intestinal microbiota metabolites in feces and serum.

NCT ID: NCT05366244 Recruiting - COVID-19 Clinical Trials

An Observational Study in Patients With Mild to Moderate COVID-19

Start date: May 2, 2022
Phase:
Study type: Observational

The purpose of this study was to observe real-world disease progression in mild-moderate COVID-19 patients with at least one risk factor for serve COVID-19 illness or death.

NCT ID: NCT05365152 Recruiting - Diabetes Clinical Trials

The Effect of Meal Replacement on the Time to Reach the Blood Glucose Target in Patients With Type 2 Diabetes Mellitus

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

This study was designed as a randomized controlled study. It was planned to include 100 patients with type 2 diabetes who received short-term intensive insulin therapy and randomly divided them into a meal replacement intervention group and a conventional diabetes diet group according to 1:1. Both groups were treated with short-term intensive insulin therapy to control blood sugar. .

NCT ID: NCT05364866 Recruiting - Clinical trials for Cardiovascular Diseases

CAB Versus Medical Therapy in Patients With AF and HF With Different EF Categories

Start date: May 1, 2022
Phase:
Study type: Observational

This study is to assess the effectiveness and safety of cryoballoon ablation comparing with medical therapy in patients with atrial fibrillation and heart failure with different ejection fraction categories.

NCT ID: NCT05364619 Recruiting - Clinical trials for Helicobacter Pylori Infection

Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

This is an open-label, randomized controlled trial. The aim of the study is to evaluate the efficacy and safety of the Qingre Huashi Granules combined the modified dual therapy (or called high dose dual therapy) for Helicobacter pylori infection specifically in geriatric patients, compared with the bismuth containing quadruple therapy. A total of 160 eligible patients will be enrolled in 4 hospitals. The eradication rate, symptoms, and the adverse events will be recorded and analyzed.

NCT ID: NCT05364177 Recruiting - Multiple Myeloma Clinical Trials

68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma

Start date: August 11, 2021
Phase: Early Phase 1
Study type: Interventional

Chemokine receptor-4 (CXCR4) is overexpressed in multiple myeloma (MM) cells. 68Ga-pentixafor is a radio-labled tracer for CXCR4 . 68Ga-pentixafor PET/CT has shown good diagnostic performance in MM. But an exchange of Ga3+ by Lu3+ or Y3+ will lead to a significant loss of CXCR4 affinity. Investigators conduct this prospective study to evaluate the diagnostic performance of 68Ga-pentixather compared with 68Ga-pentixafor, in order to parallel 68Ga-pentixather and 177Lu/90Y-pentixather in theranostics of MM.